Please ensure Javascript is enabled for purposes of website accessibility

Why Adverum Biotechnologies Stock Is Soaring Today

By George Budwell - May 5, 2020 at 10:42AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Adverum's lead gene therapy candidate continues to impress in its early-stage trial.

What happened

Adverum Biotechnologies (ADVM 3.36%), a clinical-stage gene therapy company, is off to a particularly good start today. Specifically, the biotech's shares are up by a healthy 25%, on extremely heavy volume, as of 9:39 a.m. EDT Tuesday. 

Adverum's shares are blasting higher this morning in response to a positive clinical update for the company's experimental gene therapy candidate ADVM-022. Yesterday the company announced that the therapy was showing signs of robust efficacy and an acceptable safety profile in an early-stage dosing study in patients with wet age-related macular degeneration (wet AMD). 

A researcher in a lab coat pointing to an enlarged piece of DNA.

Image source: Getty Images.

So what

Adverum is essentially attempting to upend the $10 billion wet AMD drug market with ADVM-022. The basic idea is to supplant the current host of drugs -- such as Avastin, Lucentis, and Eylea -- with a one-and-done gene therapy. Based on the data so far, it seems ADVM-022 may in fact be able to achieve this lofty goal. What's more, the company even has a shot at growing the wet AMD market by leaps and bounds by increasing compliance among elderly patients. So this sizable move northward does have a solid rationale behind it.    

Now what

Is this red-hot biotech stock still a buy? While it could be a few more years before ADVM-022 is ready for its commercial debut, gene therapy companies have been exceedingly hot commodities on the merger-and-acquisition scene for a while now. So it wouldn't be surprising if one or more suitors emerged from the shadows in the wake of this impressive early-stage data. That being the case, risk-tolerant investors may want to grab a few shares of this top gene therapy play soon. 


George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Adverum Biotechnologies, Inc. Stock Quote
Adverum Biotechnologies, Inc.
$1.54 (3.36%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.